Track topics on Twitter Track topics that are important to you
Alkermes announced the initiation of its rolling submission of a New Drug Application (NDA) to the FDA, seeking marketing approval of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action, for the adjunctive treatment of major depressive disorder (MDD). The company expects to complete the submission of the NDA for this […]
The post Alkermes initiates ALKS 5461 NDA for major depressive disorder appeared first on CenterWatch News Online.
Original Article: Alkermes initiates ALKS 5461 NDA for major depressive disorderNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...